← Human Trials & Peer-Reviewed Studies
30 Days Mortality Prognostic Value of POCT Bio-Adrenomedullin and Proenkephalin in Patients with Sepsis in the Emergency Department
Plain-language guide to PMID 36556987 (2022): observational study of Adrenomedullin in 30 patients.
Key Facts
- PMID
- 36556987
- Journal
- Medicina (Kaunas, Lithuania)
- Year
- 2022
- Study type
- Observational Study
- Authors
- Casalboni S et al. (15 authors)
- DOI
- 10.3390/medicina58121786
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Adrenomedullin, published as an observational study.
Background and Objective: Sepsis is a worldwide severe disease with a high incidence and mortality rate.
The aim of this study was to evaluate the utility of Bio-ADM and PenKid, obtained through a point of care (POCT) device, in predicting 30 days mortality for patients presenting to the ED with sepsis.
Why It Was Studied
Sepsis is a frequent cause of admission to the emergency department (ED).
Although prognostic scores (Sequential Organ Failure Assessment, SOFA; New Early Warning Score, NEWS; Rapid Emergency Medicine Score, REMS) are commonly used for risk stratification in septic patients, many of these scores are of poor utility in the ED.
Who Took Part
The study group was 30 patients.
By PubMed's age tags, the people studied were adults.
Methods and Results: In total, 177 consecutive adult patients with a diagnosis of sepsis presenting to the ED of San Giovanni Addolorata Hospital in Rome, Italy, between May 2021 and April 2022 were enrolled in this prospective observational study.
What Was Measured
Although prognostic scores (Sequential Organ Failure Assessment, SOFA; New Early Warning Score, NEWS; Rapid Emergency Medicine Score, REMS) are commonly used for risk stratification in septic patients, many of these scores are of poor utility in the ED.
The subject headings attached to it are Prognosis, Adrenomedullin, Point-of-Care Systems, Sepsis, Biomarkers, Emergency Service, Hospital and Hospital Mortality.
The authors tagged it with the keywords Bio-ADM, POCT IB10 and PenKid.
What This Means in Plain Language
This is an observational study of Adrenomedullin in 30 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2022 (Medicina (Kaunas, Lithuania)), a journal based in Switzerland.
More context: the Adrenomedullin compound page, all human trials.
Our Notes on the Compound
Adrenomedullin: A 52-amino-acid peptide that widens blood vessels; studied as an infusion in heart, lung and gut conditions.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.